Celares GmbH
Home  |  Contact  |  Imprint
celares GmbH celares GmbH celares GmbH celares GmbH celares GmbH
 
 
 

News release

News release

Merck Millipore and celares GmbH
announce collaboration

New: Discrete 4-arm-PEG Maleimide

New: Discrete 4-arm-PEG Maleimide

The multimerisation with discrete 4-arm PEG facilitates defined linker lenght according to binding requirments

Hydrophilic linkers for ADCs

Hydrophilic linkers for ADCs

celares PEG based linker increase solubility of hydrophobic cytotoxic drugs

News & Press Releases

Merck Millipore and celares announce collaboration

Merck Millipore and celares announce collaboration

Merck Millipore Adds Protein PEGylation to Portfolio of Services for Biopharmaceutical Industry through Collaboration with celares GmbH

 

  • Services include feasibility studies, process and analytical development and scale-up
  • Scales from milligram quantities to processes ready for CMO transfer
  • PEGylation helps overcome pharmacological and physicochemical challenges and accelerates time to market of protein therapeutics

Berlin, Germany, July 27, 2015 – Merck Millipore, the Life Science business of Merck, and celares GmbH today announced a collaboration with celares GmbH to provide PEGylation services to customers developing protein-based therapeutics and biosimilars. The new service offering enabled by the collaboration includes feasibility studies, process and analytical development, and scale-up from milligram to gram quantities required for pilot and subsequent commercial scale.

BioProcess Special Report

BioProcess Special Report

PEGylation of Biologics

A Multipurpose Solution

CampusNews 1/11

CampusNews 1/11

celares weltweit gefragt

Interview mit den Geschäftsführern der celares GmbH Günther Pätz, Dr. Ralf Krähmer und Dr. Frank Leenders

Neuartige Wirkstoffe profitieren von etabliertem Polymer

Neuartige Wirkstoffe profitieren von etabliertem Polymer

DRUG DISCOVERY Die Berliner Firma Celares bietet Hilfe bei der Formulierung biologischer Wirkstoffe und hat eine eigene Palette Polyethylenglykol- basierter Reagenzien zur Modifikation von Peptiden und Proteinen entwickelt. Zusammen mit Scil Proteins wurde gerade eine neuartige PEGylierungsmethode patentiert.

Campus Berlin Buch

Campus Berlin Buch

Forscher und BioTechs schaffen Voraussetzungen für individualisierte Therapien

BioTOPics 43 Biomaterials in Medicine

BioTOPics 43 Biomaterials in Medicine

For decades, biomaterials have been an integral part of medical practice. The biologization of biomaterials, however, is a relatively new trend. Increasingly, biomolecules are used for drug delivery, medical products are functionalised using biomolecules, and innovative biomaterials are created based on models from nature. Berlin-Brandenburg is positioned excellently in the material sciences field and is rapidly becoming a pacemaker for the newest generation of innovative biomaterials.